Pathogen Discovery by Lipkin, W. Ian
Opinion
Pathogen Discovery
W. Ian Lipkin*
Center for Infection and Immunity, Mailman School of Public Health of Columbia University, New York, New York, United States of America
‘‘What has become clear to you
since we last met?’’
—Benjamin Franklin
Discovery—literally, the act of uncover-
ing—implies a new and fundamental ob-
servation that changes the way in which we
view and respond to the world (Image 1).
Eureka (‘‘I have found it’’) moments are
rare in science. Given the physiques of
many scientists, this may be a good thing.
Legend has it that when Archimedes
discovered while bathing that the volume
of an object could be calculated by finding
the volume of water it displaced, he leaped
out of the bathtub and ran naked through
the streets of Syracuse proclaiming his
discovery.
The rate of discovery of new microbes,
and of new associations of microbes with
health and disease, has accelerated over
the past two decades. Many factors are
implicated. New pathogens have truly
emerged with the globalization of travel
and trade, changes in demographics and
land use, susceptibility to opportunistic
organisms associated with immunosup-
pression, and climate change [1]. New
molecular technologies such as MassTag
PCR [2–5], microbial microarrays [6–9],
and unbiased high throughput sequencing
(HTS) [10] have enabled efficient micro-
bial surveillance and discovery. The data-
bases needed to recognize sequences as
host or microbial have improved dramat-
ically. Sample collection has become
sophisticated and comprehensive. Last,
but not least, our models for pathogenesis
embrace increasingly complex mecha-
nisms that consider host–microbe–timing
interactions in acute and chronic disease.
Proof of Causation
Finding an organism is only one step in
establishing a causal relationship or un-
derstanding how it causes disease. Many
have wrestled with the challenge of
codifying the process of proving causation.
Based on the germ theory of disease of
Pasteur, Koch and Loeffler proposed
criteria that define a causative relationship
between agent and disease: the agent is
present in every case of a disease; it is
specific for that disease; and it can be
propagated in culture and inoculated into
a naı ¨ve host to cause the same disease
[11]. Known as Koch’s postulates, these
criteria were modified by Rivers for viruses
[12], and by Fredericks and Relman to
reflect the introduction of molecular
methods [13]. Although fulfillment of
Koch’s postulates remains the most per-
suasive evidence of causation, there are
problems with holding to this standard.
Overlap in signs and symptoms due to
infection with different agents is common.
Results of infection may vary with genetic
background, age, nutrition, and previous
exposure to similar agents. Many agents
cannot be cultured; furthermore, there
may be no animal model. Proving causa-
tion is particularly challenging where
agents have remote effects or require co-
factors for expression. In many acute
infectious diseases, the responsible agent
is readily implicated because it replicates
at high levels in the affected tissue at the
time the disease is manifest, morphological
changes consistent with infection are
evident, the agent is readily identified with
classical or molecular methods, and there
is evidence of an adaptive immune re-
sponse. However, implication is more
difficult when classical hallmarks of infec-
tion are absent or mechanisms of patho-
genesis are indirect or subtle. Here, one
may resort to a statistical assessment of the
strength of epidemiological association
based on the presence of the agent or its
footprints (nucleic acid, antigen, and
preferably, an immune response), and
biological plausibility as indicated by
analogy to diseases with other organisms
where linkage is persuasive.
Pathways to Pathogenesis
Implication of an agent is easiest if it is
present in high concentration at the site of
disease when the disease is manifest.
Examples include poliomyelitis, where
death of infected motor neurons results
in paralysis, or infectious diarrheas where
the causative agent (bacterium, virus, or
parasite) is found in the gastrointestinal
tract. More complex examples of intoxi-
cation occur in botulism or tetanus, where
replication in the subcutaneous tissues or
the gastrointestinal tract results in release
of toxins that have remote effects on the
nervous system. Pathogenesis may be
immune-mediated as in hepatocellular
carcinoma due to persistent hepatitis B
or hepatitis C infections [14,15]. Infection
can also impair immune function, opening
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observation dates back to the early 1900s
when von Pirquet noted the loss of skin
reactivity to tuberculin in association with
measles infection [16]; however, it is now
best known in the context of HIV/AIDS.
The effects of infection may depend on the
age and maturation status of the host.
Individuals at either extreme of life are at
increased risk for morbidity and mortality
[17–19]. Infection during organogenesis
may have different consequences than at
other times. Birth defects can accompany
prenatal infection with toxoplasma, rubel-
la-, cytomegalo-, and herpesviruses [20].
Persistent viral infections can have subtle
effects on cellular physiology that result in
alterations in the expression of neurotrans-
mitters or hormones that have profound
effects, including cognitive impairment
[21], hypothyroidism [22], or diabetes
mellitus [23]. Infection can break toler-
ance for ‘‘self,’’ resulting in autoimmune
disease [24]. Autoimmunity may be re-
stricted to the tissue in which the agent
replicates, presumably because host anti-
gens in that tissue are presented in a new
context. However, cross-reactive immune
responses may have an impact at a
distance as in molecular mimicry, where
streptococcal infection in the pharynx or
the skin results in immunity to the heart
and brain, causing valvular disease and
chorea, respectively [25,26]. The constel-
lation of direct and indirect pathways to
disease, short and long term, poses chal-
lenges for pathogen discovery.
Strategies for Pathogen
Discovery
Although reviews on pathogen surveil-
lance and discovery typically focus on the
latest molecular technologies, it is impor-
tant to emphasize the pivotal roles of
clinical acumen, pathology, serology, and
classical culture techniques. Clinicians and
epidemiologists are the prime movers in
pathogen discovery. They recognize the
appearance of new syndromes, collect
materials for investigation, and persuade
their colleagues to take up the search.
Anatomic pathology can be instrumental
in directing molecular work. The discov-
eries of Nipah virus [27] and West Nile
virus [28–31] were facilitated by demon-
stration of henipavirus and flavivirus
proteins in tissues, which allowed focused
consensus PCR analyses. Classical virolog-
ical methods such as tissue culture and
serology proved pivotal in the 2003 SARS
outbreak [32]. Propagation of a virus in
tissue culture enabled its rapid character-
ization by consensus and random PCR
cloning, microarray, and electron micros-
copy.
The advent of methods for cloning
nucleic acids of microbial pathogens
directly from clinical specimens ushered
in a new era in pathogen discovery. Over
the past two decades, subtractive cloning,
expression cloning, consensus PCR, and
high throughput pyrosequencing resulted
in identification of novel agents associated
with both acute and chronic diseases,
including Borna disease virus, hepatitis C
virus, Sin Nombre virus, HHV-6, HHV-8,
Bartonella henselae, Tropheryma whippelii, Ni-
pah virus, SARS coronavirus, and Israel
Acute Paralysis virus [10,27,32–40].
The most familiar molecular assays in
clinical microbiology are singleplex PCR
assays designed to detect and quantitate
the burden of individual candidate organ-
isms. These have revolutionized blood
banking, drug management of HIV, and
containment of outbreaks of infectious
disease. Degenerate primers can be em-
ployed in singleplex PCR assays at re-
duced stringency to facilitate detection of
related but unknown organisms. However,
clinical manifestations are not typically
pathognomonic of infection with specific
pathogens; thus, unless an investigator has
clues to narrow a search, this is a
cumbersome strategy even if samples,
resources, and time are sufficient to invest
in many singleplex assays for different
agents.
In contrast, multiplex assays simulta-
neously entertain many hypotheses. The
number of candidates considered can
range from less than ten with multiplex
PCR, to thousands with microarrays, to
the entire tree of life with HTS. Costs and
ease of use are improving; nonetheless,
only multiplex PCR assays are widely used
at present. In microarrays and HTS, many
genetic targets compete for assay compo-
nents (e.g., nucleotides, polymerases, and
dyes), in some instances with different
efficiencies. This abrogates quantitation
and reduces sensitivity.
A Staged Strategy for Pathogen
Detection and Discovery
Costs of pathogen discovery can be
contained by staging investment. Where
epidemiology, serology, or pathology sug-
gest one or a few candidates, singleplex
PCR is ideal. Where no such clues pertain
or singleplex assays fail, syndromic multi-
plex PCR assays allow rapid examination
of up to 30 candidates with only a modest
increase in time and expense. Microarrays
are indicated if multiplex PCR fails. Each
of these methods requires that an agent be
related to one already known. Agents
novel or sufficiently distant in sequence
to confound hybridization may require
subtractive cloning or HTS. Irrespective of
the route that results in identification of a
candidate, subsequent steps include quan-
titation of pathogen burden in affected
hosts and controls, detailed characteriza-
tion of the pathogen for features that may
contribute to virulence or provide clues to
provenance, and serology as an index to
acute infection and as a tool to examine
prevalence of infection over time and
geography.
Future Perspectives
Nucleic acid platforms are continually
evolving, enabling faster, more sensitive,
and less expensive methods for direct
microbial detection. Improvements in
development for these platforms include
microfluidic sample processing and direct
measurement of conductance changes
with hybridization. Proteomics and host
response profiling may yet yield diagnostic
biomarkers. The most advanced technol-
ogy will fail if samples are degraded, and
data will be uninterpretable without accu-
rate information on clinical course and
sample provenance; thus, emphasis should
be placed on engaging clinicians as equal
partners. In chronic diseases, early expo-
sure and/or genetic susceptibility may
influence pathogenesis. The most substan-
tive advances in linking microbes to
disease may come from investments in
prospective serial sample collections and
models wherein diseases reflect intersec-
tions of genes and environment in a
temporal context.
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